Based on Research Conducted at OSLC
Adolescent substance abuse results in significant negative outcomes for youths, their families, communities, and society. Rates of psychiatric comorbidity, or dual diagnosis, among substance-abusing youths range from 25 to 82 percent. Treatment of these youths is both costly and complicated, with youth and their families often having to navigate separate treatment services for each disorder. […]
Project Overview
Adolescent substance abuse results in significant negative outcomes for youths, their families, communities, and society. Rates of psychiatric comorbidity, or dual diagnosis, among substance-abusing youths range from 25 to 82 percent. Treatment of these youths is both costly and complicated, with youth and their families often having to navigate separate treatment services for each disorder. As well, treatment of youths with co-occurring disorders is often ineffective, with youth returning to pre-treatment levels of substance use often and more rapidly than youths without a psychiatric disorder. This study (NIDA #R01DA025616) was a randomized clinical trial that compared an experimental treatment (OutPatient Treatment for Adolescents) to an “active placebo” on key indices (drug use; mental health; behavioral, school, peer, and family functioning; and consumer satisfaction) from pre-treatment through 18 months in order to evaluate its efficacy for youth referred to outpatient treatment of co-occurring substance use and internalizing problems.
MAP-OPT A References
Sheidow, A. J., Zajac, K., Chapman, J. E., McCart, M. R., & Drazdowski, T. K. (2021). Randomized controlled trial of an integrated family-based treatment for adolescents presenting to community mental health centers. Community Mental Health Journal, 57(6), 1094-1110. PMCID: PMC8081741
Year Project Began: 2014Funder: National Institute on Drug Abuse
Co-Investigator:
Formerly Affiliated Principal Investigator:
- Ashli J. Sheidow, Ph.D.
Formerly Affiliated Co-Investigator:
- Jason E. Chapman, Ph.D.